CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive internal research license. DUBLIN and CHESHIRE, United Kingdom ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

CRISPR-Cas9 technology – which allows scientists to precisely cut and modify DNA at specific locations within a genome – was discovered by Jennifer Doudna and Emmanuelle Charpentier in 2012.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...